Reimagining Pediatric Drug Development to Transform Lives

Join us in delivering new therapies to children with cancer and rare diseases.

Our Mission

We are a non-profit biotechnology division of CobiCure, a company within Advancium Health Network, committed to bringing life-changing therapeutics to patients by utilizing philanthropic funding and strategic partnerships. We manage a portfolio of projects addressing high-impact needs in the underserved markets of pediatrics and rare diseases.

More About Us About Advancium

Pediatric cancers and rare diseases are underfunded and underserved:

More than 300M children worldwide suffer from a rare diease. ¹
95% of rare diseases do not have approved treatments. ²
30% of children with a rare disease won’t live to see their fifth birthday. ³

Source
1 - www.rarediseaseday.org
2 & 3 - www.rarediseases.org

We are building an accelerator to deliver life-changing products to children by:

In-licensing, acquiring or co-developing therapeutic assets that will reduce patient morbidity and mortality

Partnering with leading experts and funders with similar goals to leverage exceptional skills and resources

Advancing assets through late-stage R&D, clinical trials, and regulatory clearance/approval

Help us Make an Impact

We are seeking funders and collaborators to advance our mission. How you can help:

Make a financial contribution to support our work
Connect us to drug development programs aligned with our mission
Share your expertise

News at CobiCure Therapeutics

Frankel Foundation Ignites $10 Million Accelerator at CobiCure for Pediatric Clinical Development

Landmark investment establishes dedicated accelerator to fast-track life-saving innovations to accelerate clinical development for pediatric medical devices and therapies for childhood cancer and rare diseases

Changing the Business Model for Pediatric Rare Diseases CobiCure’s Mission: Overcoming Barriers to Deliver Effective Treatments to Children Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma Real Stories: Why CobiCure’s Mission Matters to Our CEO, Mark Veich